Advancing Predictions of Oral Drug Absorption, CYP3A4 Induction, and Transporter‐Mediated Interactions Using a Human Primary Intestinal 3D Model ( EpiIntestinal™ )
Clinical Pharmacology & Therapeutics · 2025-12 · 118 (6) · 1499-1511
DOI: 10.1002/cpt.70000 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical Pharmacology & Therapeutics, online erschienen am 14.07.2025. Verfasst von Paresh P Chothe und 4 weiteren Autor:innen. Beteiligte Einrichtung: Drug Metabolism and Pharmacokinetics, Oncology Research and Development, AstraZeneca, Waltham, Massachusetts, USA. Hauptthemen laut MEDLINE: Cytochrome P-450 CYP3A, Models, Biological, Intestinal Absorption, Cytochrome P-450 CYP3A Inducers. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 41 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Accurate prediction of oral drug absorption in humans is essential for early drug development; however, physiologically relevant human models are lacking. This study aims to comprehensively assess the EpiIntestinal™, a human primary intestinal 3D model, for its ability to predict oral absorption ( F a ), intestinal availability ( F g ), CYP3A4 induction, and drug–drug interactions (DDIs). The model showed clinically relevant expression of a key drug‐metabolizing enzymes, transporters, and a nuclear receptor, pregnane X receptor (PXR). The model demonstrated a moderate improvement over Caco‐2 in correlating permeability coefficients with human absorption data for a set of 18 drugs. However, PBPK modeling, using EpiIntestinal™ permeability data, accurately predicted the clinical maximum plasma concentration ( C max ) of the P‐gp substrates digoxin and dabigatran etexilate, unlike the significant underpredictions from Caco‐2 data. PBPK modeling using intrinsic clearance and permeability data from EpiIntestinal™ accurately predicted human F g for CYP3A4/5 substrate drugs (except buspirone). Furthermore, the model demonstrated the induction of CYP3A4 and P‐gp (threefold) by a strong PXR inducer, rifampicin. Combining induction parameters of rifampicin from EpiIntestinal™ with those from the TruVivo (human hepatic model) into PBPK modeling accurately captured DDI effects on midazolam, a sensitive CYP3A4/5 substrate. Additionally, the model accurately predicted clinical outcomes of P‐glycoprotein (P‐gp) and breast cancer resistance protein (BCRP) mediated DDIs for ARV‐471. These data underscore the potential of EpiIntestinal™ in predicting human F a and F g , and in quantitatively assessing CYP3A4 induction and transporter‐based DDIs.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Drug Metabolism and Pharmacokinetics, Oncology Research and Development, AstraZeneca, Waltham, Massachusetts, USA.
ORCID-Profile: Paresh P Chothe, Aniruddha Karve, Diane Ramsden, Niresh Hariparsad
Zitieren
APA
Chothe, P. P., Whitcher-Johnstone, A., Karve, A., Ramsden, D., & Hariparsad, N. (2025). Advancing Predictions of Oral Drug Absorption, CYP3A4 Induction, and Transporter‐Mediated Interactions Using a Human Primary Intestinal 3D Model ( EpiIntestinal™ ). Clinical Pharmacology & Therapeutics, 118(6), 1499-1511. https://doi.org/10.1002/cpt.70000
Vancouver
Chothe PP, Whitcher-Johnstone A, Karve A, Ramsden D, Hariparsad N. Advancing Predictions of Oral Drug Absorption, CYP3A4 Induction, and Transporter‐Mediated Interactions Using a Human Primary Intestinal 3D Model ( EpiIntestinal™ ). Clinical Pharmacology & Therapeutics. 2025;118(6):1499-1511. doi:10.1002/cpt.70000
BibTeX
@article{Chothe2025,
author = {Chothe, Paresh P and Whitcher-Johnstone, Andrea and Karve, Aniruddha and Ramsden, Diane and Hariparsad, Niresh},
title = {Advancing Predictions of Oral Drug Absorption, CYP3A4 Induction, and Transporter‐Mediated Interactions Using a Human Primary Intestinal 3D Model ( EpiIntestinal™ )},
journal = {Clinical Pharmacology & Therapeutics},
year = {2025},
volume = {118},
number = {6},
pages = {1499--1511},
doi = {10.1002/cpt.70000}
}
EUVIMED